|
(P866) |
Identification of key lipids critical for platelet activation by comprehensive analysis of the platelet lipidome |
| |
|
S. Geue, B. Peng, C. Coman, D. Kopczynski, N. Hoffmann, M.-C. Manke, F. Lang, M. Gawaz, R. Ahrends, O. Borst (Tübingen, Dortmund) |
|
(P867) |
Phenylacetic acid impairs PGI2 sensitivity in platelets by reactive oxygen species generation and links chronic kidney disease to a prothrombotic phenotype |
| |
|
M. Berger, K. Lysaja, E. Heibrok, S. Maxeiner, K. Naseem, N. Marx, K. Schütt (Aachen; Leeds, UK) |
|
(P868) |
C3a receptor on platelets – essential part in the crosstalk of platelets with the complement system |
| |
|
R. J. Sauter, M. Sauter, H. Nording, J. Patzelt, J.-C. Reil, H. Langer (Tübingen, Lübeck) |
|
(P869) |
Platelet micro-RNAs as a predictor of cardiovascular risk – results from the EXCELSIOR-thrombomiR study |
| |
|
T. Nührenberg, M. Hackl, A. Kille, C. M. Valina, C. Stratz, D. Trenk, F.-J. Neumann, W. Hochholzer (Bad Krozingen; Wien, AT) |
|
(P870) |
Platelet-derived calpain mediates protease-activated receptor 1-dependent vascular inflammation in diabetes |
| |
|
A. Kyselova, A. Elgheznawy, I. Wittig, W. Ruf, I. Fleming, V. Randriamboavonjy (Frankfurt am Main, Mainz) |
|
(P871) |
Deletion of platelet CD40 ligand alters neointima formation and in-vitro thrombus formation but does not affect atherosclerosis in mice. |
| |
|
M. Ahmadsei, C. Weber, D. Atzler, N. Gerdes (München, Düsseldorf) |
|
(P873) |
Role of RXR on platelet function and arterial thrombosis - a RXR- deficient mouse model |
| |
|
E. Lüsebrink, V. Warm, J. Pircher, A. Ehrlich, P. Chambon, S. Massberg, C. Schulz, T. Petzold (München; Strasbourg, FR) |